Search

A range of isatin-thiazolidinone hybrid analogues were synthesized and their cytotoxicity was evaluated against several cancer cell lines in vitro. The acute toxicity studies in mice models revealed that these analogues possess low systemic toxicity and are safe up to 1600mg/Kg. Among the compounds synthesized, 5-(2-nitrobenzylidene)-2-(isatin-3-azino)-thiazolidin-4-one (CI) has been shown to be the most active, highly promising compound which induced S phase arrest in cell cycle in a time dependent manner. Our initial analysis indicate that incorporation of electron withdrawing group at ortho position of the ring favors over the meta and para positions for eliciting its cytostatic effect. Overall, the in vitro biological evaluation suggests that the growth inhibitory effect of CI is promising and can be studied further.

Peroxisomal proliferator activated receptor gamma (PPARgamma) belongs to the family of nuclear hormone receptors (NHRs), which directly regulate transcription of target genes. The regulatory role of this receptor on lipid metabolism and insulin sensitization is well established. Recently, the overexpression of this receptor in many human cancers has been identified and understanding its biological significance forms the current theme. PPARgamma activation by specific agonists leads to growth inhibition, apoptosis and differentiation of tumor cells. PPARgamma possess evident tumor promoting properties but the receptor independent effects of its ligands compound the understanding of its biology in cancers. This review highlights the multifaceted role of PPARgamma in cancer progression with specific reference to colon, breast, gastric, lung and urological cancers. Molecular events as well as the mediators involved are analyzed in detail along with PPARgamma independent effects of ligands under each cancer type. The crucial cross talk that exists between Wnt and PPARgamma signaling is also summarized. An attempt has been made to identify the existing lacunae in understanding the biology of PPARgamma in cancers along with suggestions for possible rectification.

Magnetic resonance imaging (MRI) contrast agents are utilized adjunctively to enhance the contrast between normal and abnormal structures on MRI scans. Along with the rapid evolution of the field has come a new appreciation for the medicinal chemistry of this unique class of metallopharmaceuticals. The efficacy of MRI agents is a complex function of chemical, biophysical, and pharmacological properties, which must be married in a package of exquisite safety. This report illustrates the wide range of medicinal chemistry relevant to existing agents that are either approved or in clinical development, as well as concepts, which may result in exciting new pharmaceuticals in the future.